Press release

Siemens Healthineers fully on track after successful second quarter

Siemens Healthineers AG today announces its results for the second quarter, ending March 31, of fiscal year 2023.

Published on May 10, 2023

Q2 Fiscal Year 2023 

  • Equipment orders continued to exceed very strong equipment revenues; equipment book-to-bill ratio 1.01 
  • Comparable revenue growth was very good at 11.2% excluding rapid COVID-19 antigen tests; taking into account the tapering rapid antigen test business, comparable revenue declined by 2.5% from a very strong prior-year quarter 
  • Imaging showed clear comparable revenue growth of 12.7% and a strong improvement in adjusted EBIT margin of 130 basis points to 21.5% 
  • Diagnostics revenue fell 39.0% on a comparable basis due to the tapering rapid COVID-19 antigen test business; adjusted EBIT margin of -10.1% burdened by transformation costs (€77 million, or 710 basis points) 
  • Varian achieved excellent comparable revenue growth of 27.0% following resolution of a previous supply-chain issue; adjusted EBIT margin at 14.4% 
  • Advanced Therapies showed very strong comparable revenue growth of 9.9%; adjusted EBIT margin clearly higher than in the prior-year quarter at 16.8%; endovascular robotics solution will focus exclusively on neurovascular interventions 
  • Overall adjusted EBIT margin was down to 12.7% due to lower contributions from rapid COVID-19 antigen tests, transformation costs in Diagnostics, and cost increases, particularly for procurement and logistics 
  • Adjusted basic earnings per share were below the prior-year quarter at €0.43; excluding rapid antigen tests and transformation costs, adjusted basic earnings per share increased by 11%

Outlook for Fiscal Year 2023 

We confirm our expectation for comparable revenue growth of -1% to 1% (6% to 8% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of €2.00 to €2.20. 

Bernd Montag, CEO of Siemens Healthineers AG: 

»We achieved remarkable sales growth in the second quarter and made important decisions for the future. We are fully on track to achieve our annual and mid-term targets.«

Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at